GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (STU:GE91) » Definitions » Shiller PE Ratio

Genmab A/S (STU:GE91) Shiller PE Ratio : 46.32 (As of May. 14, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Shiller PE Ratio?

As of today (2024-05-14), Genmab A/S's current share price is €26.40. Genmab A/S's E10 for the quarter that ended in Mar. 2024 was €0.57. Genmab A/S's Shiller PE Ratio for today is 46.32.

The historical rank and industry rank for Genmab A/S's Shiller PE Ratio or its related term are showing as below:

STU:GE91' s Shiller PE Ratio Range Over the Past 10 Years
Min: 45.64   Med: 122.51   Max: 477.78
Current: 46.47

During the past years, Genmab A/S's highest Shiller PE Ratio was 477.78. The lowest was 45.64. And the median was 122.51.

STU:GE91's Shiller PE Ratio is ranked worse than
64.24% of 151 companies
in the Biotechnology industry
Industry Median: 36.15 vs STU:GE91: 46.47

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Genmab A/S's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.271. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €0.57 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab A/S Shiller PE Ratio Historical Data

The historical data trend for Genmab A/S's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Shiller PE Ratio Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 173.93 146.70 112.08 85.33 52.55

Genmab A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.90 69.95 62.05 52.55 48.67

Competitive Comparison of Genmab A/S's Shiller PE Ratio

For the Biotechnology subindustry, Genmab A/S's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Shiller PE Ratio falls into.



Genmab A/S Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Genmab A/S's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=26.40/0.57
=46.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab A/S's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Genmab A/S's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.271/116.7000*116.7000
=0.271

Current CPI (Mar. 2024) = 116.7000.

Genmab A/S Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.006 99.700 -0.007
201409 0.037 99.700 0.043
201412 0.016 99.400 0.019
201503 0.049 100.200 0.057
201506 0.004 100.300 0.005
201509 0.031 100.200 0.036
201512 0.086 99.800 0.101
201603 -0.003 100.200 -0.003
201606 0.037 100.600 0.043
201609 0.041 100.200 0.048
201612 0.183 100.300 0.213
201703 0.003 101.200 0.003
201706 0.067 101.200 0.077
201709 -0.001 101.800 -0.001
201712 0.170 101.300 0.196
201803 0.043 101.700 0.049
201806 0.056 102.300 0.064
201809 0.039 102.400 0.044
201812 0.180 102.100 0.206
201903 0.016 102.900 0.018
201906 0.018 102.900 0.020
201909 0.111 102.900 0.126
201912 0.308 102.900 0.349
202003 0.055 103.300 0.062
202006 0.689 103.200 0.779
202009 0.108 103.500 0.122
202012 0.118 103.400 0.133
202103 0.223 104.300 0.250
202106 0.062 105.000 0.069
202109 0.181 105.800 0.200
202112 0.135 106.600 0.148
202203 0.095 109.900 0.101
202206 0.385 113.600 0.396
202209 0.526 116.400 0.527
202212 0.104 115.900 0.105
202303 0.043 117.300 0.043
202306 0.277 116.400 0.278
202309 0.433 117.400 0.430
202312 0.130 116.700 0.130
202403 0.271 116.700 0.271

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab A/S  (STU:GE91) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Genmab A/S Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (STU:GE91) Business Description

Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (STU:GE91) Headlines

No Headlines